ALS Diagnosis via Biomarker Panel Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing amyotrophic lateral sclerosis (ALS) are slow and require extensive specialist consultations, resulting in a mean time of 13-18 months from symptom onset to confirmation of diagnosis.
Innovation Solution
A method involving the determination of the quantitative or qualitative level of specific biomarkers such as PDIA3, CCDC80, HSPA8, and DAG1 in biological samples to diagnose or prognose ALS, utilizing a panel of biomarkers to facilitate quicker diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional specialist consultation methods are used for ALS diagnosis, then diagnostic accuracy can be maintained through comprehensive evaluation, but diagnostic time increases to 13-18 months
Solution Approach 1:
The patent extracts and measures specific biomarkers (DAG1, PLEC, HSPA5, NCL, TPM1, TNC, IGFBP3, COL5A1, CLEC11A, MAP1B, NACA, PSMA2, RPL5, MYL6, CTSB, HSPD1, PTRF, NUCB1, PDIA4, P4HB, ACTN4, EEF1D, TPI1, SSBP1, PSMB8, PSAP, PSMB7, CAPZA1, PRDX1, PODN, MMP1, NUCB2, HMGB1, AHNAK, FNDC1, DENR, PENK, S100A11, RPL29, RPL27, RPL8, SRSF2, SF3B4, SBSN, LYAR, NUDC, CRLF1, TGFB1, CAT, CTSD, DLD, EPB41L2, PSMB9, RPS14, RPL7A, COLEC12, SMARCC2, TAGLN2, CCT4, ASPH, GPS1, CDK13, SH3GL2, HBA1, APEX1, PSMB5, TXN, AXL, RPS8, SET, RPS18, CFL1, DMKN, RPL22, RPL6, FKBP10, PAFAH1B1, S100A13, PSMA6, SERPINE1, CAPRIN1, SEPT7, VTN, ENPP2, NEO1, DKC1, CHI3L1, SKOR1, SSRP1, COL4A2, NME1, CFB, EIF2S3, DPYSL2, NUMA1, KTN1, CHID1, EFEMP1, YWHAZ, LDHB, SDCBP, TLN1, DES, APP) from biological samples to diagnose ALS, replacing the need for prolonged specialist consultations while maintaining diagnostic accuracy
Solution Approach 2:
The patent uses biomarkers as intermediary substances that mediate the diagnosis process. These biomarkers serve as measurable indicators that bridge the gap between clinical symptoms and definitive diagnosis, enabling faster identification of ALS cases without requiring extended specialist evaluation periods
2Measurement precision
If a comprehensive panel of biomarkers is measured to improve diagnostic accuracy, then measurement complexity and cost increase
Solution Approach 1:
The patent segments the diagnostic process into measuring multiple individual biomarkers (DAG1, PLEC, HSPA5, NCL, TPM1, TNC, IGFBP3, COL5A1, CLEC11A, MAP1B, NACA, PSMA2, RPL5, MYL6, CTSB, HSPD1, PTRF, NUCB1, PDIA4, P4HB, ACTN4, EEF1D, TPI1, SSBP1, PSMB8, PSAP, PSMB7, CAPZA1, PRDX1, PODN, MMP1, NUCB2, HMGB1, AHNAK, FNDC1, DENR, PENK, S100A11, RPL29, RPL27, RPL8, SRSF2, SF3B4, SBSN, LYAR, NUDC, CRLF1, TGFB1, CAT, CTSD, DLD, EPB41L2, PSMB9, RPS14, RPL7A, COLEC12, SMARCC2, TAGLN2, CCT4, ASPH, GPS1, CDK13, SH3GL2, HBA1, APEX1, PSMB5, TXN, AXL, RPS8, SET, RPS18, CFL1, DMKN, RPL22, RPL6, FKBP10, PAFAH1B1, S100A13, PSMA6, SERPINE1, CAPRIN1, SEPT7, VTN, ENPP2, NEO1, DKC1, CHI3L1, SKOR1, SSRP1, COL4A2, NME1, CFB, EIF2S3, DPYSL2, NUMA1, KTN1, CHID1, EFEMP1, YWHAZ, LDHB, SDCBP, TLN1, DES, APP) separately, allowing for systematic and standardized measurement of each biomarker to improve overall diagnostic accuracy while managing measurement complexity through structured analysis
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~4
AI summary
The present invention relates to a method of diagnosing or prognosing a neurological disorder in a subject. The method comprises determining the quantitative or qualitative level of one or more biomarkers in a biological sample from the subject; and diagnosing or prognosing the neurological disorder in the subject based on the quantitative or qualitative level of the or each biomarker in the biological sample.